Blast Crisis (Blast Phase)

Subscribe to Selected New Research on Blast Crisis

941 relevant articles (75 outcomes, 87 trials/studies) found for this Disease

Description: An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.

Also Known As:

Blast Phase; Blast Crises; Blast Phases; Crises, Blast; Crisis, Blast; Phase, Blast; Phases, Blast

Relationship Network

Disease Context: Research Results

Related Diseases

1.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
3.	Leukemia
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
5.	Myelodysplastic Syndromes (Myelodysplastic Syndrome)
93 Diseases and 585 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Cortes, Jorge: 4 articles (09/2007 - 05/2002)
2.	Druker, Brian J: 4 articles (09/2007 - 05/2002)
3.	Hochhaus, Andreas: 4 articles (04/2007 - 05/2002)
4.	Hochhaus, A: 3 articles (07/2007 - 04/2003)
5.	Duyster, J: 2 articles (07/2007 - 02/2005)
6.	von Bubnoff, N: 2 articles (07/2007 - 02/2005)
7.	Peschel, C: 2 articles (07/2007 - 02/2005)
8.	Ohyashiki, Kazuma: 2 articles (06/2007 - 02/2002)
9.	Gotoh, Akihiko: 2 articles (06/2007 - 02/2002)
10.	Sashida, Goro: 2 articles (06/2007 - 02/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Blast Crisis:

1.	imatinib (Gleevec)FDA Link 05/01/2008 - "Imatinib mesylate (IM) is a new drug which has been shown to induce complete hematological remission in 55% and complete cytogenetic response in 22% of the patients with CML in blast crisis" 06/01/2006 - "Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate." 01/15/2006 - "Among 541 patients treated with imatinib in chronic phase, 23 developed blast phase, which was of sudden onset (ie, occurring in patients previously in complete cytogenetic remission) in 4 patients (17%; 0.7% of the total), 2 lymphoid and 2 myeloid" 09/01/2002 - "Imatinib is effective in chronic phase, accelerated phase and blast crisis, with lower response rates in patients with more advanced disease" 01/01/2004 - "Imatinib mesylate is also effective in patients with accelerated-phase and blast-crisis CML, and patients with chronic-phase CML who have failed IFNalpha therapy" Get all the results and reference details, order at left...
2.	Cytarabine (Cytosar-U)FDA LinkGeneric 07/01/1986 - "We conclude that high-dose ara-C is an effective regimen for CML blast crisis, resulting in a substantial response rate but modest remission duration" 01/01/1987 - "A Phase II study of high dose cytosine arabinoside (ara-C) with different schedules in patients with recurrent acute myelogenous leukaemia (AML) and myeloid blast crisis of chronic myeloid leukaemia has been conducted at St. Bartholomew's Hospital" 06/01/2003 - "With a median follow-up of 14 months, a maximum follow-up of 19.5 months, and an expected median survival of 5-6 years on the IFN-alpha/cytarabine control arm, few of the expected progressions to accelerated or blast phase or deaths have occurred" 11/01/1993 - "The cytotoxic potency of Aza-dC was comparable or even greater than that of 1-beta-D-arabinofuranosylcytosine (Ara-C) in most cases, suggesting that this drug has potential in the therapy of blast crisis of CML" 11/01/1991 - "Its use in 5-day induction courses for blast crisis CML has a response rate comparable to that achieved with high-dose Ara-C" Get all the results and reference details, order at left...
3.	Interferon-alpha (Interferon Alfa)FDA Link 04/15/1997 - "In a group of patients treated with alpha-interferon (n = 32), those with normal TRFs had a significantly lower frequency of blast crises (P = 0.0328), a significantly higher incidence of cytogenetic responses (P = 0.0185), and a favorable prognosis (P < 0.01) compared with those with shortened TRFs" 01/01/2007 - "It is also indicated in paediatric patients with newly diagnosed Ph+ chronic-phase CML, in accelerated-phase or blast-crisis CML, or in chronic-phase CML after failure of interferon-alpha therapy or when the disease has recurred after haematopoietic stem cell transplantation (HSCT)" 10/01/1996 - "The model was sensitive to the monthly cost of interferon-alpha therapy (if the cost of interferon-alpha is reduced by one third, the cost-effectiveness becomes $19300 per quality-adjusted year of life saved) but was not particularly sensitive to the costs associated with blast crisis or bone marrow transplantation" 08/01/2000 - "We report the previously undescribed occurrence of extramedullary blast crisis in a patient with chronic myelogenous leukemia in complete cytogenetic and molecular remission on interferon-alpha" 08/01/2000 - "Extramedullary blast crisis in a patient with chronic myelogenous leukemia in complete cytogenetic and molecular remission on interferon-alpha therapy." Get all the results and reference details, order at left...
4.	Hydroxyurea (Hydrea)FDA LinkGeneric 04/01/2002 - "We report a case of secondary Ph - ve MDS/AML during blast crisis in a patient treated with hydroxyurea for CML." 02/01/1993 - "In patient 2, although good control of the platelet counts was achieved with hydroxyurea, the disease also evolved into a blast crisis four months after diagnosis" 09/15/1983 - "In 5 cases, treatment with hydroxyurea was successful in lowering circulating WBC counts, but was of questionable value in the prevention of leukemic blast crisis." 04/01/2002 - "After treatment with hydroxyurea for 7 months, the disease progressed to a blast crisis" 08/01/1999 - "The survival was longer for patients transplanted in accelerated phase (vs blast crisis), those who were due to receive a double transplant (vs single) (34 patients), those who were treated with IFN after transplant (vs hydroxyurea) and for the patients who obtained a complete hematologic response." Get all the results and reference details, order at left...
5.	Vincristine (Oncovin)FDA LinkGeneric 04/01/1983 - "In vitro assay of the effects of vincristine on CFU-C appears to have predictive value for in vivo response in blast crisis of CGL." 04/01/1983 - "The in vitro sensitivity of circulating progenitor cells (CFU-C) of 20 patients in blast crisis of chronic granulocytic leukemia (CGL) to vincristine was correlated with the clinical response to vincristine in vivo" 04/01/1983 - "The in vitro effects of vincristine on peripheral blood leukocyte progenitor cells (CFU-C) in patients in blast crisis of chronic granulocytic leukemia: correlation with clinical response." 01/01/1985 - "Although generally well tolerated, prolonged infusion of vincristine appears to have limited activity in the treatment of refractory acute nonlymphoblastic leukemia and blast crisis of chronic granulocytic leukemia; further evaluation is needed in acute lymphoblastic leukemia refractory to conventional bolus injection." 01/01/1988 - "The response to uniform vincristine and prednisolone (V + P) therapy has shown that lymphoid blast crisis cases were highly responsive in contrast to the cases with non-lymphoid blast crisis (complete remission rate 86 vs 21.4%)" Get all the results and reference details, order at left...
6.	Busulfan (Busulfex)FDA Link 08/01/1999 - "Fifty-two other patients (group II) were transplanted for CML in transformation (accelerated phase = 32; blast crisis = 20) after a preparative regimen containing either total body irradiation (TBI) or busulfan" 05/01/1991 - "Four weeks later, she passed into frank blast crisis, despite treatment with busulphan and palliative radiotherapy to the lymph nodes." 03/01/1992 - "Treatment with busulfan led to no improvement; instead in September 1986 he developed blast crisis with ANLL M4Eo morphology" 10/01/1989 - "Lymphadenopathy regressed on busulphan therapy and the overt blast crisis took 15 months to occur after initial presentation." 01/01/1984 - "Busulfan had a pronounced cytoreductive effect on circulating leukemic cells in the late, pre-blast crisis stage of this disease but all treated animals, succumbed to the leukemia with only a marginal increase in survival time relative to that of untreated controls" Get all the results and reference details, order at left...
7.	Prednisone (Sone)FDA LinkGeneric 12/01/1984 - "Phase II study of the treatment of CML blast crisis with vindesine and prednisone]" 12/01/1989 - "The NK lymphocyte blast crisis was successfully treated with vincristine and prednisone" 06/01/1989 - "These results were compared to a historical control group of 31 patients with myeloid blast crisis treated with vincristine and prednisone" 06/30/1982 - "Five of 40 patients with chronic myeloid leukemia (CML) had lymphoid blast crisis and 4 of them achieved complete remission of metamorphosis with vincristine and prednisone" 02/01/1994 - "Thus, a remission was seen during treatment with vincristine, prednisone, and MPA after a deterioration with vincristine and prednisone alone in a PR-positive leukemia, and an effect of MPA in this lymphoid blast crisis of a CML has to be discussed." Get all the results and reference details, order at left...
8.	Plicamycin FDA Link 01/01/1987 - "These results suggest that plicamycin may be effective in suppressing proliferation of blasts and promoting their maturation in the myeloid blast phase of CML, but that plicamycin alone may not be effective enough to sustain duration of response." 01/01/1991 - "Failure of mithramycin to control the myeloid blast phase of chronic granulocytic leukemia: a report on nine patients and review of the literature." 01/01/1987 - "Two cases in myeloid blast phase of chronic myelogenous leukemia (CML) responded to treatment with plicamycin alone" 12/04/1986 - "We observed a dramatic improvement in the peripheral blood counts of a patient in the myeloid blast phase of chronic granulocytic leukemia after plicamycin (mithramycin) therapy of concurrent hypercalcemia" 07/01/1990 - "In conclusion, combination use of vincristine and mithramycin may be useful in the treatment of the myeloid blast crisis." Get all the results and reference details, order at left...
9.	Mitoxantrone (Novantrone)FDA LinkGeneric 11/01/1985 - "From another patient in blast crisis (of myeloblastic phenotype), only Ph1-positive lines were established initially; however, five months later, after the patient had been treated with mitoxantrone, only Ph1-negative lines were derived from this patient" 01/01/1985 - "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)" 03/01/1991 - "Mitoxantrone is a dihydroxyanthracenedione derivative which as intravenous mono- and combination therapy has demonstrated therapeutic efficacy similar to that of standard induction and salvage treatment regimens in advanced breast cancer, non-Hodgkin's lymphoma, acute nonlymphoblastic leukaemia and chronic myelogenous leukaemia in blast crisis; it appears to be an effective alternative to the anthracycline component of standard treatment regimens in these indications" 08/01/1993 - "In an effort to determine if cell cycle active agents are augmented when given after non-cell cycle active agents, 104 patients with either multiply relapsed or refractory acute nonlymphocytic leukemia or blast crisis of chronic myelogenous leukemia were treated with mitoxantrone" 09/01/1984 - "An increase in mitoxantrone dose to 12 mg/m2/d produced complete remissions in 8 of 19 evaluable patients with acute nonlymphoblastic leukemia, in one of ten patients with refractory acute nonlymphoblastic leukemia, and in one of four patients with chronic granulocytic leukemia in blast crisis" Get all the results and reference details, order at left...
10.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/01/1996 - "Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease." 08/01/2000 - "In the present study, we demonstrated that the proliferation of leukemic cells from chronic myeloid leukemia in blast crisis (CML-BC) and Ph1-positive acute lymphoblastic leukemia (ALL) cases is frequently stimulated with G-CSF in vitro" 08/01/2000 - "Participation of granulocyte colony-stimulating factor in the growth regulation of leukemia cells from Philadelphia chromosome-positive acute leukemia and blast crisis of chronic myeloid leukemia." 07/01/1997 - "To determine if mutations of the G-CSF-R are more widespread in hematological malignancies, we have investigated a total of 47 patients, including 29 patients with blast crisis of chronic myeloid leukemia (CML-BC) and 18 patients with de novo acute leukemia as well as 19 normal controls, by RT-PCR and SSCP analysis" 11/01/1995 - "Fifty seven patients with acute leukemia (35 cases of refractory acute myeloid leukemia, 19 cases of acute lymphoblastic leukemia and 3 cases of blast crisis of chronic myeloid leukemia) were given G-CSF under either of the following two conditions; 1) Group A: starting G-CSF (200 micrograms/m2iv) administration 24 hrs after chemotherapy" Get all the results and reference details, order at left...
391 Drugs and Important Bio-Agents and 832 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 10/01/2002 - "Blast crisis recurred during subsequent intensification chemotherapy and the patient did not go into a complete remission regardless of the intense chemotherapy" 03/01/1991 - "After a single cycle of induction, all lymphoid cases displayed a complete restoration of Ph1-negative hemopoiesis; by contrast, one myeloid blast crisis showed a partial suppression of Ph1-positive hemopoiesis only after two cycles of chemotherapy, and in the remaining two cases the hematological remission was indeed a reversion to the chronic phase" 05/01/2005 - "Several doses of intrathecal chemotherapy and whole-brain irradiation were effective in treating the blast crisis in the CNS" 01/01/1984 - "The median survival, the rate of decline in survival, and the remission rate in blast crisis do not appear to differ from those of comparable groups of patients treated with chemotherapy alone." 12/01/1984 - "At the time of the present study, the patient was five years post-diagnosis and had been off chemotherapy for two months following a year of treatment for lymphoid blast crisis" Get all the results and reference details, order at left...
2.	Transplants (Transplant) 02/01/2005 - "DESIGN AND METHODS: The study population comprised 647 (60%) males and 437 (40%) females, with a median age of 32 years old (range 1 - 59); 898 (83%) were in chronic phase, 146 (13%) were in accelerated phase and 40 (4%) were in blast crisis; 151 (14%) were younger than 20 years old, 620 (57%) were between 20 and 40 and 313 (29%) were older than 40; 1,025 (94%) received an HLA fully matched sibling transplant and only 59 (6%) received an unrelated transplant" 04/01/2001 - "At transplant, six patients were in chronic phase (five in first, and one in second), two in blast crisis, and one in accelerated phase" 11/01/2000 - "Of the 6 CML, 1 had fractionated bone marrow and is surviving at 3 years, and 5 had standard single dose infusion and died of progression of their disease after rejection of the graft (4) or blast crisis after complete engraftment (1)" 01/01/2000 - "We describe a 5-year-old girl with Ph(+) CML who received a cord blood transplant in a second accelerated phase after a very early lymphoid blast crisis" 02/15/1996 - "When cells from patients with CML in either myeloid or lymphoid blast crisis were transplanted into SCID mice, the BM of these mice was more rapidly repopulated and to a higher level than that observed with transplants of chronic phase cells" Get all the results and reference details, order at left...
3.	Transplantation (Transplant Recipients) 08/01/2008 - "At transplantation, the median patient age was 39 years (range, 1-67 years); 38 patients were in chronic phase (CP), 13 in the accelerated phase (AP) and 35 in blast crisis (BC)" 03/01/2006 - "Successful cord blood transplantation in a minor BCR-ABL+ CML patient who had been in lymphoid blast crisis at presentation." 04/01/2005 - "The patient who underwent transplantation in blast crisis died on day 21 (too early to be evaluated for engraftment) from progressive disease" 01/01/2004 - "MATERIAL AND METHODS: 44 ABM transplantations were performed in 37 CML patients in the chronic phase and 7 patients in acceleration or blast crisis" 12/01/1998 - "He underwent a second transplantation in early second blast crisis, 92 months after the first BMT with PBPC from his previous donor" Get all the results and reference details, order at left...
4.	Stem Cell Transplantation 12/01/2006 - "A total of 69 patients were recruited with male/female ratio of 7:3. Of the 69 patients; 35% were in the chronic phase, 41% were in the accelerated phase, 17% were in blast crisis and the remaining 7% were after stem cell transplantation" 01/19/2002 - "Subsequently the patient in blast crisis underwent allogeneic stem-cell transplantation" 09/01/1997 - "Autologous stem cell transplantation was performed, but relapse occurred 11 months after blast crisis" 09/01/2008 - "We analyzed the outcomes of 74 patients diagnosed with BCR-ABL(-) myeloproliferative neoplasms in blast phase receiving induction chemotherapy (55%), low-intensity therapy (16%), stem cell transplantation (SCT; 3%), or supportive care (26%)" 04/15/2007 - "BACKGROUND: Despite advances in drug therapy and allogeneic stem cell transplantation (allo-SCT), the prognosis of patients with chronic myeloid leukemia (CML) in blast crisis remains poor" Get all the results and reference details, order at left...
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 07/01/1998 - "Response did allow one patient to proceed to bone marrow transplantation and two other patients to continue therapy for chronic phase disease before returning to blast crisis" 01/01/1994 - "Seven patients were in first chronic phase and the other 3 were in blast crisis, second chronic phase, and relapse post-bone marrow transplantation (BMT), respectively" 10/01/1992 - "A 47-year-old patient was treated with allogeneic bone marrow transplantation (BMT) for chronic myelogenous leukaemia in blast crisis" 07/01/1992 - "Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: a report of five cases." 01/08/1988 - "Since at present there are no reliable risk factors for the occurrence of acceleration or blast crisis, bone marrow transplantation should be undertaken as early as possible in the chronic phase of CML." Get all the results and reference details, order at left...
21 Therapies and Procedures and 199 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician
Research Summary Report
on Blast Crisis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 75 Outcomes
Top 200 Key Medications
Top 21 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details